Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Tag: TRIPS flexibilities
Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
Medicines Law & Policy
-
April 12, 2022
Wrapping up 2021 – some noteworthy medicines law and policy events
Ellen 't Hoen
-
December 24, 2021
Landmark decision by the World Health Assembly to start negotiations for...
Kaitlin Mara
-
December 1, 2021
TRIPS Council to discuss IP and the public interest in the...
Ellen 't Hoen
-
July 29, 2020
Never say never – Why the High Income Countries that opted-out...
Christopher Garrison
-
April 8, 2020
Covid-19 and the comeback of compulsory licensing
Ellen 't Hoen
-
March 23, 2020
The Expanding Reach of the European Patent Office. Good for Health?
Ellen 't Hoen
-
March 18, 2020
Uganda tells ARIPO: No more patents for pharmaceuticals
Ellen 't Hoen
-
October 8, 2019
Corbyn’s Compulsory Licenses. Will they work?
Ellen 't Hoen
-
September 26, 2019
Strong call for transparency on medicine prices, cost of R&D at...
Ellen 't Hoen
-
April 19, 2019
1
2
Page 1 of 2
This work is licensed under Creative Commons.